Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06289673 · ClinicalTrials.gov registry record · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
A Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 850
- Enrollment target
- 3
- Study locations
NCT06289673: Recruiting Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia, sponsored by St. Jude Children's Research Hospital.
NCT06289673 is a Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 850 participants, above the 376-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (126% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06289673, a Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 850 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
Primary Outcome
The proportion of patients with sufficient immunophenotypic, genomic, and clinical data to allow determination of eligibility for currently open trials at the enrolling institution.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Daunorubicin
- DRUG Methotrexate
- DRUG Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Study Locations (3)
California
- Rady Children's Hospital - San Diego
Oklahoma
- Saint Francis Children's Hospital - Tulsa
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2039-05 |
| Phase | Phase 4 |
What NCT06289673 shows while recruiting
NCT06289673 is an interventional study that assigns participants to a tested intervention. The registered 850 participants enrollment target is mid-sized for trials with a published cap, above the 376-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (126% higher).
The record links to 3 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT06289673 reports a single indexed study location in California, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06289673 about?
NCT06289673 is a clinical study titled "Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma". The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * ...
What is the current status of trial NCT06289673?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 850 participants. The study started on 2024-12-26. Estimated completion is 2039-05.
What conditions does trial NCT06289673 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT06289673?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Daunorubicin (DRUG), Methotrexate (DRUG), Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) (DRUG).
Who is sponsoring clinical trial NCT06289673?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06289673 being conducted?
This trial has 3 study locations across California, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06289673's enrollment target sits among peer trials
850 9th of 131 higher than 123 of 131 other Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03507257 · 850 participants
Longitudinal Early-onset Alzheimer's Disease Study Protocol
- NCT05846841 · 850 participants · NA
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
- NCT05987059 · 850 participants · Phase 2
Involving Communities in Addressing the Maternal Health Crisis: Making an IMPACT
- NCT06526195 · 850 participants · NA
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI